Over two evening events in Sydney and Melbourne, medical device company InMode will host Canadian optometrist Dr Bruce Dornn to discuss his experience with the Envision platform for dry eye disease (DED).
Dornn is considered an early adopter of Envision – which he began using around four years ago – and will be presenting at exclusive dinner events at:
- QT Hotel Sydney, 16 October, 6.30-9pm
- QT Hotel Melbourne, 17 October, 6.30-9pm
The Envision platform is of interest to Australian practitioners who gained access to the technology earlier in 2023. It is described as a non-surgical, non-drug alternative for DED comprising three distinct technologies.
The platform adopts both radio frequency (Forma-I) and intense pulsed light (Lumecca-I) for the effective treatment of meibomian gland dysfunction and DED. A third – and complementary – treatment is MORPHEUS8 that adopts fractional radio frequency microneedling for complete face and body dermal resurfacing, tightening and subdermal remodelling.
Insight interviewed Dornn about his experience with the Envision platform in May 2023 when he described how the technology transformed the clinical and commercial performance of his practice.
“Envision has been a game changer for my practice as I can effectively treat the cause of dry eye disease with life-changing results, plus with Morpheus8 I can build an additional income stream by tightening the skin in the periorbital area and full face,” Dornn said.
More information about the events can be found here.
More reading
InMode brings new dry eye care approach to Australia
Positive findings for InMode Envision platform in dry eye study
Australia dry eye disease update – 2023
